Gynecomastia is the thing people in this space worry about most and understand least. It gets blamed on oestrogen generally, treated with whatever is nearest to hand, and discovered too late to reverse.

The mechanism is well established and it is worth knowing properly, because the two main drug classes used against it work in completely different ways and are not interchangeable.

What Gynecomastia Actually Is

Gynecomastia is proliferation of glandular breast tissue in males. That word, glandular, is the whole point.

The male chest contains a small amount of breast tissue that is present from birth and normally stays dormant. It has oestrogen receptors. When oestrogen signalling at those receptors rises past a threshold and stays there, the ductal tissue proliferates: cells divide, ducts lengthen and branch, and connective tissue builds around them.

That is a structural change, not a fluid or fat change. Which leads to the part people find out the hard way.

Why It Does Not Reverse

In the early phase, the tissue is actively proliferating and inflamed, and the process can be interrupted. This is the window where it presents as tenderness, itching, or a small firm lump behind the nipple.

If oestrogen signalling stays elevated for months, the proliferative tissue is progressively replaced by fibrous tissue. Fibrosis is not hormone responsive. At that point nothing pharmacological removes it, because the thing that is left is scar-like connective tissue rather than hormone-sensitive gland.

This is why the timeline matters more than the severity. A small amount of established fibrotic tissue is permanent. A larger amount of early proliferative tissue often is not.

The Oestrogen Route

The common route is aromatisation. Aromatase converts testosterone into estradiol, and the enzyme is present in adipose tissue, so there is more of it in heavier individuals.

When exogenous androgen raises the substrate pool, estradiol rises with it. The androgen to oestrogen ratio is what the tissue responds to, not oestrogen alone, which is why identical oestrogen readings produce different outcomes in different people.

Aromatase inhibitors act here. Anastrozole and exemestane, both in the AE and PCT range, reduce the conversion itself, so less estradiol is produced. The mechanism of the second of those is set out in Understanding Aromasin.

The Prolactin Route

There is a second route that aromatase inhibitors do nothing about, and missing it is a common and expensive mistake.

The 19-nor compounds, nandrolone and trenbolone among them, have progestogenic activity. Progesterone receptor agonism can drive prolactin, and prolactin acting on breast tissue produces lactational changes and proliferation through a pathway that has nothing to do with aromatase.

Someone running a 19-nor who develops symptoms, tightens aromatase inhibition, and sees no improvement is usually dealing with this rather than with estradiol. The compound class is discussed in Deca Durabolin (Nandrolone).

Prolactin and estradiol are separate lines on a blood panel. Guessing between them is unnecessary.

Why SERMs Are Not the Same as AIs

Selective oestrogen receptor modulators, tamoxifen being the familiar one, do not reduce oestrogen. They occupy the receptor in breast tissue and block the signal there while behaving differently in other tissues.

So an AI lowers the hormone and a SERM blocks the receptor. In breast tissue the end result looks similar, but systemically they are not the same intervention at all, and they have different effects on lipids, bone and the pituitary. Tamoxifen’s broader profile is covered in The Ultimate Guide to Enhancing Testosterone With Nolvadex.

Which class is appropriate depends on which pathway is driving the problem, and that is a clinical question rather than a forum one.

Who Is More at Risk

Risk is not evenly distributed, and three factors account for most of the variation.

Body fat is the first. Aromatase is expressed in adipose tissue, so a higher body fat percentage means more conversion capacity from the same substrate. Two people on identical compounds at identical doses can land in different places for this reason alone.

Genetic receptor sensitivity is the second, and it is the one nobody can screen for in advance. Tissue responsiveness to oestrogen signalling varies between individuals, which is why identical estradiol readings produce symptoms in one person and nothing in another.

A history of pubertal gynecomastia is the third. Adolescent gynecomastia is common and usually resolves, but residual tissue that was once primed remains more responsive later. Anyone who had it as a teenager is starting from a different baseline.

Compound choice sits on top of all three. Anything that aromatises heavily raises the oestrogen route, and anything in the 19-nor family opens the prolactin route as well. The orals range and the injectables differ substantially on both counts.

Why It Can Appear After a Cycle Ends

A common and counterintuitive pattern is symptoms starting once exogenous androgen stops rather than while it is running.

The reason is the ratio. Endogenous testosterone production is suppressed and takes time to recover, so androgen levels fall quickly. Oestrogen, meanwhile, falls more slowly, and aromatase activity in adipose tissue does not switch off on the same timeline. For a period the androgen to oestrogen ratio is worse than it was at any point during the cycle.

That window is the reason recovery protocols exist at all, and it is covered in Why Post Cycle Therapy Is Essential. It is also why stopping abruptly in response to early gyno symptoms occasionally makes them worse before it makes them better.

What It Is Not

Not every change in chest appearance is gynecomastia.

Pseudogynecomastia is subcutaneous fat, soft and diffuse, with no discrete mass behind the nipple and no tenderness. It tracks body fat and responds to body composition rather than to hormones.

True gynecomastia presents as a firm, often tender, discrete disc of tissue centred on the areola. The distinction is usually obvious on palpation and definitive on imaging, and it determines whether a hormonal intervention is even relevant.

Why Bloodwork Is the Whole Answer

Everything above resolves to a small number of measurements: total and free testosterone, estradiol on a sensitive assay, and prolactin. Those three readings separate the aromatase route from the prolactin route and separate real elevation from an imagined one.

Symptoms alone cannot do this. Tenderness feels the same whichever pathway caused it. What a panel actually tells you, and what it does not, is covered in What Bloodwork Actually Tells You During a Cycle.

One technical point that matters here: standard immunoassay estradiol panels are unreliable in males, particularly at the low end, and can read substantially off. A sensitive assay, usually specified as estradiol by LC-MS or an ultrasensitive method, is the one worth requesting. Acting on a bad number is worse than acting on no number, because it produces confident intervention in the wrong direction. Questions about testing generally are answered in the FAQ.

The Short Version

Gynecomastia is glandular proliferation driven by oestrogen or prolactin signalling. It is reversible while it is proliferative and permanent once it has fibrosed, so the early window is the one that counts. Aromatase inhibitors lower oestrogen production, SERMs block the receptor, and neither addresses a prolactin-driven case. Which one is relevant is a blood panel question, not a guess.